I-Mab (IMAB)
NASDAQ: IMAB
· Real-Time Price · USD
4.32
0.19 (4.60%)
At close: Oct 03, 2025, 3:59 PM
4.40
1.85%
After-hours: Oct 03, 2025, 06:07 PM EDT
4.60% (1D)
| Bid | 4.32 |
| Market Cap | 353.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.21M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -8.47 |
| Forward PE | -2.06 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 4.5 |
| Volume | 1,962,435 |
| Avg. Volume (20D) | 2,224,569 |
| Open | 4.34 |
| Previous Close | 4.13 |
| Day's Range | 4.27 - 4.50 |
| 52-Week Range | 0.59 - 5.90 |
| Beta | 1.46 |
| Ex-Dividend Date | n/a |
About IMAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 days ago
+4.6%
I-MAB shares are trading higher after Leerink Part...
Unlock content with
Pro Subscription
1 month ago
+8.07%
I-MAB shares are trading higher on possible continued strength after reporting a year-over-year increase in Q2 EPADS results on Wednesday. Additionally, Needham raised its price target on the stock from $5 to $6 on Thursday.
3 weeks ago · seekingalpha.com
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketI-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with promisi...
